anticarcinogen

(redirected from anticancer drug)
Also found in: Dictionary, Medical.

anticarcinogen

[′an·tē‚kär′sin·ə·jən]
(pharmacology)
Any substance which is antagonistic to the action of a carcinogen.
References in periodicals archive ?
Combination therapy using angiogenesis inhibitors and anticancer drugs can improve drug delivery into tumour tissues and prolong progression-free survival.
BEL-7402/5-FU cells and BEL-7402 cells were seeded into 96-well plates (1 x [10.sup.4] cells/well) and incubated with various concentrations of anticancer drugs (0-150 [micro]M DMC, 0-1 mg/ml 5-FU and 0-8 [micro]g/ml DOX.
GPC Biotech is a biotechnology company discovering and developing new anticancer drugs. The company's lead product candidate - satraplatin - is currently in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer following successful completion of a Special Protocol Assessment by the United States FDA and receipt of a Scientific Advice letter from the European regulatory authority, EMEA.
Wayne Jowett,18, was recovering from leukaemia when Dr Fed a Mulhem made a fatal error and ordered a junior colleague to inject a powerful anticancer drug into his spine.
Prosecutors had alleged that Waksal illegally advised family members to sell their company stock after he learned on December 26 that the Food and Drug Administration had nixed approval of an anticancer drug called Erbitux, which the company had developed and had been hoping to market.
The Nagoya District Court on Friday ordered Aichi Prefecture to pay 34 million yen in compensation to the family of a woman who died at a prefectural hospital from an overdose of an anticancer drug that was being clinically tested.
M2 EQUITYBITES-May 26, 2017-PharmaMar signs licensing agreement in Turkey with EczacA[+ or -]baAYA[+ or -] for anticancer drug Aplidin
M2 PHARMA-May 26, 2017-PharmaMar signs licensing agreement in Turkey with EczacA[+ or -]baAYA[+ or -] for anticancer drug Aplidin
Santiago announced that she had lung cancer in July 2014, but announced last year that had already beaten the disease after undergoing a clinical trial for a new anticancer drug.
Furthermore, the antioxidant ability of Vitamin D is compared to that of the anticancer drug tamoxifen and its 4-hydroxy metabolite (structural mimics of cholesterol) and discussed in relation to the anticancer action of this vitamin.
In addition to the substantial capex associated with anticancer drug manufacturing capacity it is worth underlining that these types of assets are rarely suitable for producing other types of products, further compounding risks of capital and asset obsolescence.